| Bioactivity | Pasotuxizumab (BAY 2010112) is a PSMA and CD3 bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with KDs of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC)[1][2]. |
| Target | KDs: 9.4 nM and 16.3 nM for human and cynomolgus monkey CD3.KDs: 47.0 nM and 212.6 nM for human and cynomolgus monkey PSMA. |
| Invitro | Pasotuxizumab (约 0-100 ng/mL，48 小时) 可激活 CD4+ 和 CD8+ T 细胞群，EC50 为 3.4-6.7 ng/mL (人) 和 13.7-21.2 ng/mL (食蟹猴)[2]。Pasotuxizumab (约 0-100 ng/mL，48 小时) 增加 T 细胞中干扰素-γ、TNF-α、IL-2 和 IL-10 的释放[2]。 |
| In Vivo | Rafivirumab (0.005-5 mg/kg，尾静脉注射，每日一次) 抑制 PC-3-huPSMA 小鼠异种移植模型中的肿瘤生长[2]。Rafivirumab (0.1-1 mg/kg，静脉推注给药) 在 BALB/c 小鼠中表现出较低的血清清除率[2]。 Animal Model: |
| Name | Pasotuxizumab |
| CAS | 1442657-12-6 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Horst-Dieter Hummel, et al. Phase 1 study of pasotuxizumab (BAY 2010112), a PSMA-targeting Bispecific T cell Engager (BiTE) immunotherapy for metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology 2019 37:15_suppl, 5034-5034. [2]. Friedrich M, et al. Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens. Mol Cancer Ther. 2012 Dec;11(12):2664-73. |